Craft

Knight Therapeutics

Stock Price

$5.6

2024-10-29

Market Capitalization

$570.8 M

2024-10-29

Revenue

$450.1 M

FY, 2025

Knight Therapeutics Summary

Company Summary

Overview
Knight Therapeutics is a specialty pharmaceutical company focused on acquiring, in-licensing, selling, and marketing prescription and over-the-counter pharmaceutical products. It also invests in finances of other life sciences companies with the goal of securing product distribution rights. The company focuses on a range of therapeutic areas, including oncology, inflammatory diseases, fungal infections, chronic hepatitis C, and more.
Type
Public
Status
Active
Founded
2014
HQ
Westmount, CA | view all locations
Website
https://knighttx.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • James C. Gale

    James C. Gale, Chairman of the Board

    • Samira Sakhia

      Samira Sakhia, President

      • Jonathan Ross Goodman, Director, CEO and Founder

        • Amal Khouri

          Amal Khouri, Vice-President, Business Development

          LocationsView all

          1 location detected

          • Westmount, QC HQ

            Canada

            1055-3400 Maisonneuve Blvd W

          Knight Therapeutics Financials

          Summary Financials

          Revenue (Q1, 2026)
          $C148.4M
          Gross profit (Q1, 2026)
          $C85.3M
          Net income (Q1, 2026)
          $C13.2M
          Cash (Q1, 2026)
          $C108.0M
          EBIT (Q1, 2026)
          $C12.7M
          Enterprise value
          $532.6M

          Footer menu